{"id":"placebo-to-match-mirabegron","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebos are inactive substances used in controlled trials to provide a comparator arm and minimize bias. This particular placebo is manufactured to match mirabegron (a beta-3 adrenergic agonist used for overactive bladder) in appearance, taste, and administration route, allowing trial participants and researchers to remain blinded to treatment assignment while evaluating mirabegron's efficacy and safety.","oneSentence":"This is an inert placebo formulation designed to match the physical and sensory characteristics of mirabegron for blinded clinical trial purposes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:52.201Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Placebo control for mirabegron trials in overactive bladder"}]},"trialDetails":[{"nctId":"NCT05362292","phase":"PHASE4","title":"TReating Incontinence for Underlying Mental and Physical Health","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-10-04","conditions":"Urinary Incontinence, Urge, Urinary Incontinence, Overactive Bladder","enrollment":270},{"nctId":"NCT02216214","phase":"PHASE4","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-10-07","conditions":"Overactive Bladder (OAB)","enrollment":888},{"nctId":"NCT00912964","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04-28","conditions":"Urinary Bladder, Overactive","enrollment":2030},{"nctId":"NCT00662909","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-03-28","conditions":"Urinary Bladder, Overactive","enrollment":2149},{"nctId":"NCT00688688","phase":"PHASE3","title":"Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04-25","conditions":"Urinary Bladder, Overactive","enrollment":2792},{"nctId":"NCT00689104","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04-28","conditions":"Urinary Bladder, Overactive","enrollment":2336},{"nctId":"NCT04641975","phase":"PHASE3","title":"A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-03-15","conditions":"Overactive Bladder (OAB), Pharmacokinetics of Mirabegron","enrollment":26},{"nctId":"NCT02656173","phase":"PHASE4","title":"A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-01-25","conditions":"Overactive Bladder","enrollment":568},{"nctId":"NCT02757768","phase":"PHASE4","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-06-13","conditions":"Benign Prostatic Hyperplasia, Overactive Bladder","enrollment":715},{"nctId":"NCT01972841","phase":"PHASE3","title":"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-11-05","conditions":"Urinary Bladder Overactive, Urinary Bladder Diseases\\Urologic Diseases, Overactive Bladder","enrollment":3527},{"nctId":"NCT01908829","phase":"PHASE3","title":"A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2013-07-10","conditions":"Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases","enrollment":2174},{"nctId":"NCT02045862","phase":"PHASE3","title":"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-17","conditions":"Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence","enrollment":1829},{"nctId":"NCT01340027","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2011-03-29","conditions":"Urologic Diseases, Urinary Bladder Diseases, Urological Manifestations","enrollment":1307},{"nctId":"NCT02138747","phase":"PHASE4","title":"A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-07-24","conditions":"Overactive Bladder (OAB)","enrollment":376},{"nctId":"NCT03187795","phase":"PHASE2","title":"Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury","status":"UNKNOWN","sponsor":"Kessler Foundation","startDate":"2019-04-03","conditions":"Spinal Cord Injuries, Urinary Bladder, Neurogenic","enrollment":62},{"nctId":"NCT02044510","phase":"PHASE2, PHASE3","title":"Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients","status":"TERMINATED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2014-07","conditions":"Urinary Bladder, Neurogenic","enrollment":32},{"nctId":"NCT02169713","phase":"PHASE1","title":"Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-05","conditions":"Healthy Subjects, Pharmacokinetics, Drug-Drug Interaction (DDI)","enrollment":20},{"nctId":"NCT00410514","phase":"PHASE2","title":"A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-12","conditions":"Lower Urinary Tract Symptoms, Bladder Outlet Obstruction","enrollment":200},{"nctId":"NCT01478503","phase":"PHASE1","title":"To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2005-05","conditions":"Pharmacokinetics, Healthy Subjects","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to match mirabegron","genericName":"Placebo to match mirabegron","companyName":"Astellas Pharma Europe B.V.","companyId":"astellas-pharma-europe-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is an inert placebo formulation designed to match the physical and sensory characteristics of mirabegron for blinded clinical trial purposes. Used for Placebo control for mirabegron trials in overactive bladder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}